# An Investigation of AGS-009 in Patients With Systemic Lupus Erythematosus (SLE)

> **NCT00960362** · PHASE1 · COMPLETED · sponsor: **Argos Therapeutics** · enrollment: 13 (actual)

## Conditions studied

- Inflammation
- Systemic Lupus Erythematosus (SLE)

## Interventions

- **DRUG:** AGS-009
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00960362
- **Lead sponsor:** Argos Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2012-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00960362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00960362, "An Investigation of AGS-009 in Patients With Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00960362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*